Jump to content

User:Ventus55/Wolfgang Koenig: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Citation bot (talk | contribs)
Bots
5,433,756 edits
Misc citation tidying. | Use this bot. Report bugs. | Suggested by AManWithNoPlan | #UCB_CommandLine
 
(40 intermediate revisions by 6 users not shown)
Line 1: Line 1:
[[File:Koenig Wolfgang Prof Dr Innere 2 02 UK Ulm.jpg|thumb|Wolfgang Koenig]]
[[File:Koenig Wolfgang Prof Dr Innere 2 02 UK Ulm.jpg|thumb|Wolfgang Koenig]]
'''Wolfgang Koenig''' (born 18 Dezember [[1949]] in [[Neuenbürg]]) is a [[German|Germany]] [[cardiology|cardiologist]] and university professor. He was assistant medical director at the Department of Internal Medicine II Cardiology, [[Angiology]], [[Sports medicine]] and [[Rehabilitation medicine]] at the Medical Clinic of the [[University of Ulm]]. He is known for his works in the field of evaluation of new biomarkers for cardiological disorders including population based genomics and in connection with [[inflammation]], [[hemostasis]] and [[atherosclerosis]].
'''Wolfgang Koenig''' (born 18 Dezember 1949 in [[Neuenbürg]]) is a [[Germans|German]] [[cardiology|cardiologist]] and university professor. He was assistant medical director at the Department of Internal Medicine II Cardiology, [[Angiology]], [[Sports medicine]] and [[Rehabilitation medicine]] at the Medical Clinic of the [[University of Ulm]]. He is known for his works in the field of evaluation of new [[biomarker]]s for cardiological disorders including [[population genomics]] and in connection with [[inflammation]], [[hemostasis]] and [[atherosclerosis]].


== Biography ==
== Biography ==
Koenig studied medicine at the [[Ludwig Maximilians University of Munich]] from 1969 to 1975. In 1976 he passed the [[United States Medical Licensing Examination|ECFMG]] in Munich. In 1980 he received his doctorate at the [[University of Heidelberg]]. He spent stays abroad till 1983 and was then head of the MONICA Heart Attack Register of the [[WHO]] at the [[Augsburg Hospital]] from 1983 to 1986. In 1986 Koenig went to the Medical Clinic at the [[University of Ulm]], where he became an internal medicine in 1989. From 1992 on he was a specialist for cardiology. In this year he was [[Habilitation|habilitated]] in Ulm. In 1989 he became associate professor and received the additional title Internal Intensive Care in 2005. From 1995 to 2000 Koenig was executive senior physician at the medical hospital and head of the emergency department. From 2003 to 04 he was head of the intensive care unit and from 2004 to 2005 head of the laboratory of heart catheter. Koenig was senior physician at the Department for Internal Medicine II - Cardiology at the Medical University Hospital of the University of Ulm till March 2015. There he headed the laboratory of biomarkers and the clinical center of studies. Beginning of Apil 2015 he joined the German Heart Center Munich at the [[Technical University of Munich]] mainly being scientifically active there.
Koenig studierte von 1969 bis 1975 Medizin an der [[LMU München]]. 1976 absolvierte er, ebenfalls in München, das amerikanische Staatsexamen ([[United States Medical Licensing Examination|ECFMG]]). 1976-1977 leistete er seine Zeit als Medizinalassistent am [[Klinikum Schwabing|Städtischen Krankenhauses München-Schwabing]] ab, war danach bis 1980 als Assistenzarzt an der Klinik Höhenried für Herz- und Kreislaufkrankheiten der LVA Oberbayern in Bernried tätig, bevor er 1980 an der [[Universität Heidelberg]] promovierte. Bis 1983 arbeitete er als wissenschaftlicher Assistent an verschiedenen Instituten und war von 1983 bis 1986 Leiter des MONICA-Herzinfarktregisters der [[Weltgesundheitsorganisation]] (WHO) am [[Zentralklinikum Augsburg]]. 1986 wechselte Koenig an die Medizinische Klinik der Universität Ulm. Dort wurde er 1989 Arzt für Innere Medizin und führt ab 1992 die Zusatzbezeichnung Kardiologie. Im selben Jahr habilitierte er sich mit einem Thema einer Arbeit zu den Fließeigenschaften des Blutes mit dem Titel "[[Rheologie|Blutrheologie]]: Zusammenhänge mit kardiovaskulären Risikofaktoren und der koronaren Herzkrankheit". 1998 wurde er zum außerplanmäßigen Professor ernannt und erlangte 2005 die Zusatzbezeichnung Internistische [[Intensivmedizin]]. 1995-2000 war Koenig Geschäftsführender Oberarzt der Medizinischen Klinik und Leiter der Notaufnahme, 2003-04 Leiter der Intensivstation und 2004-05 Leiter der Herzkatheterlabore. Koenig war bis Ende März 2015 Oberarzt der Abt. Innere Medizin II - Kardiologie der Medizinischen Universitätsklinik Ulm und leitete das dortige Biomarkerlabor sowie das „Klinische Studienzentrum“. Zum 1. April 2015 wechselte er an das [[Deutsches Herzzentrum München|Deutsche Herzzentrum München]] der [[TU München|Technischen Universität München]], wo er vorwiegend wissenschaftlich tätig ist.


== Scientific contribution==
== Scientific contribution==


Koenig provided long experience in research work in the range of epidemology of cardiovascular disorders (built up the MONICA Augsburg heart attack register of the [[WHO]]). He delivered fundamental contributions to the inflammation hypothesis of atherosclerosis.<ref>Koenig W, Sund M, Lowe GD, Lee AJ, Resch KL, Tunstall-Pedoe H, Keil U, Ernst E: Geographical variations in plasma viscosity and relation to coronary event rates. Lancet. 1994 Sep 10;344(8924):711-4</ref><ref>Peters A, Döring A, Wichmann HE, Koenig W. Increased plasma viscosity during an air pollution episode: a link to mortality? Lancet. 1997 May 31;349(9065):1582-7.</ref><ref>Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.Nature. 1998 Jun 25;393(6687):790-3.</ref><ref>Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999 Jan 19;99(2):237-42.</ref><ref>Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet. 2001 Mar 10;357(9258):763-7.</ref><ref>Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004 Mar 23;109(11):1349-53. Epub 2004 Mar 15.</ref><ref>Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005 Aug 2;112(5):651-7. Epub 2005 Jul 25.</ref><ref>Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006 Oct 3;48(7):1369-77.</ref><ref>Spahr A., Klein E., Khuseyinova N., Boeckh C., Pezeshki G., Muche R., Kunze M., Rothenbacher D., Hoffmeister A., Koenig W. Periodontal infections and coronary heart disease: Role of periodontal bacteria and importance of total pathogen burden. The Coronary Event and Periodontal Disease (CORODONT) Study. Arch Intern Med. 2006 Mar 13;166(5):554-9.</ref><ref>Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. JUPITER Study Group. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.</ref> <ref>Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J. 2009 Nov;30(22):2742-8. {{doi|10.1093/eurheartj/ehp302}}. Epub 2009 Aug 7.</ref><ref>Sarwar N et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Emerging Risk Factors Collaboration, Lancet. 2010 Jun 26;375(9733):2215-22. {{doi|10.1016/S0140-6736(10)60484-9}}.</ref><ref>Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lp-PLA(2) Studies Collaboration, Lancet. 2010 May 1;375(9725):1536-44. {{doi|10.1016/S0140-6736(10)60319-4}}.</ref> and to the importance of [[hemostasis|hemostaseological]] factors for [[atherogenesis]].<ref>Danesh J et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. Fibrinogen Studies Collaboration, JAMA. 2005 Oct 12;294(14):1799-809.</ref><ref>Smith NL et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010 Mar 30;121(12):1382-92. {{doi|10.1161/CIRCULATIONAHA.109.869156}}. Epub 2010 Mar 15.</ref> as well as to genetics of intermediary phenotypes of atherosclerosis.<ref>Dehghan A et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011 Feb 22;123(7):731-8. {{doi|10.1161/CIRCULATIONAHA.110.948570}}. Epub 2011 Feb 7.</ref><ref>Smith NL et al. Genetic predictors of fibrin D-dimer levels in healthy adults. Circulation. 2011 May 3;123(17):1864-72. {{doi|10.1161/CIRCULATIONAHA.110.009480}}. Epub 2011 Apr 18.</ref><ref>Sarwar N et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Lancet. 2012 Mar 31;379(9822):1205-13. {{doi|10.1016/S0140-6736(11)61931-4}}. Epub 2012 Mar 14.</ref><ref>Franceschini N et al. Discovery and fine mapping of serum protein loci through transethnic meta-analysis. Am J Hum Genet. 2012 Oct 5;91(4):744-53. {{doi|10.1016/j.ajhg.2012.08.021}}. Epub 2012 Sep 27.</ref><ref>Deloukas P et al. Large-scale association analysis identifies new risk loci for coronary artery disease. DIAGRAM Consortium; CARDIOGENICS Consortium, Nat Genet. 2013 Jan;45(1):25-33. {{doi|10.1038/ng.2480}}. Epub 2012 Dec 2.</ref><ref>Doney AS et al. CARDIoGRAMplusC4D Consortium, Nat Genet. 2013 Jan;45(1):25-33. {{doi|10.1038/ng.2480}}. Epub 2012 Dec 2.</ref><ref>Deloukas P et al. Large-scale association analysis identifies new risk loci for coronary artery disease. CARDIoGRAMplusC4D Consortium, Nat Genet. 2013 Jan;45(1):25-33. {{doi|10.1038/ng.2480}}. Epub 2012 Dec 2.</ref><ref>Berndt SI et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet. 2013 May;45(5):501-12. {{doi|10.1038/ng.2606}}. Epub 2013 Apr 7.</ref><ref>Sabater-Lleal M et al. VTE Consortium; STROKE Consortium; Wellcome Trust Case Control Consortium 2 (WTCCC2); C4D Consortium; CARDIoGRAM Consortium, Wallaschofski H, Smith NL, Tregouet D, Ridker PM, Tang W, Strachan DP, Hamsten A, O'Donnell CJ. Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease. Circulation. 2013 Sep 17;128(12):1310-24. {{doi|10.1161/CIRCULATIONAHA.113.002251}}. Epub 2013 Aug 22.</ref><ref>Holmes MV et al. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol. 2013 Nov 19;62(21):1966-76. {{doi|10.1016/j.jacc.2013.06.044}}. Epub 2013 Jul 31.</ref><ref>Shungin Dɳ̩. et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015 Feb 12;518(7538):187-96. {{doi|10.1038/nature14132}}.</ref><ref>Locke AE the al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015 Feb 12;518(7538):197-206. {{doi|10.1038/nature14177}}.</ref>
Koenig provided long experience in research work in the range of [[epidemology]] of cardiovascular disorders (built up the MONICA Augsburg heart attack register of the [[WHO]]). He delivered fundamental contributions to the inflammation hypothesis of atherosclerosis<ref>Koenig W, Sund M, Lowe GD, Lee AJ, Resch KL, Tunstall-Pedoe H, Keil U, Ernst E: Geographical variations in plasma viscosity and relation to coronary event rates. Lancet. 1994 Sep 10;344(8924):711-4</ref><ref>Peters A, Döring A, Wichmann HE, Koenig W. Increased plasma viscosity during an air pollution episode: a link to mortality? Lancet. 1997 May 31;349(9065):1582-7.</ref><ref>Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.Nature. 1998 Jun 25;393(6687):790-3.</ref><ref>Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999 Jan 19;99(2):237-42.</ref><ref>Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet. 2001 Mar 10;357(9258):763-7.</ref><ref>Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004 Mar 23;109(11):1349-53. Epub 2004 Mar 15.</ref><ref>Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005 Aug 2;112(5):651-7. Epub 2005 Jul 25.</ref><ref>Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006 Oct 3;48(7):1369-77.</ref><ref>Spahr A., Klein E., Khuseyinova N., Boeckh C., Pezeshki G., Muche R., Kunze M., Rothenbacher D., Hoffmeister A., Koenig W. Periodontal infections and coronary heart disease: Role of periodontal bacteria and importance of total pathogen burden. The Coronary Event and Periodontal Disease (CORODONT) Study. Arch Intern Med. 2006 Mar 13;166(5):554-9.</ref><ref>Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. JUPITER Study Group. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.</ref> <ref>Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J. 2009 Nov;30(22):2742-8. {{doi|10.1093/eurheartj/ehp302}}. Epub 2009 Aug 7.</ref><ref>Sarwar N et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Emerging Risk Factors Collaboration, Lancet. 2010 Jun 26;375(9733):2215-22. {{doi|10.1016/S0140-6736(10)60484-9}}.</ref><ref>Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lp-PLA(2) Studies Collaboration, Lancet. 2010 May 1;375(9725):1536-44. {{doi|10.1016/S0140-6736(10)60319-4}}.</ref> and to the importance of [[hemostasis|hemostaseological]] factors for [[atherogenesis]]<ref>Danesh J et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. Fibrinogen Studies Collaboration, JAMA. 2005 Oct 12;294(14):1799-809.</ref><ref>Smith NL et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010 Mar 30;121(12):1382-92. {{doi|10.1161/CIRCULATIONAHA.109.869156}}. Epub 2010 Mar 15.</ref> as well as to genetics of intermediary phenotypes of atherosclerosis.<ref>Dehghan A et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011 Feb 22;123(7):731-8. {{doi|10.1161/CIRCULATIONAHA.110.948570}}. Epub 2011 Feb 7.</ref><ref>Smith NL et al. Genetic predictors of fibrin D-dimer levels in healthy adults. Circulation. 2011 May 3;123(17):1864-72. {{doi|10.1161/CIRCULATIONAHA.110.009480}}. Epub 2011 Apr 18.</ref><ref>Sarwar N et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Lancet. 2012 Mar 31;379(9822):1205-13. {{doi|10.1016/S0140-6736(11)61931-4}}. Epub 2012 Mar 14.</ref><ref>Franceschini N et al. Discovery and fine mapping of serum protein loci through transethnic meta-analysis. Am J Hum Genet. 2012 Oct 5;91(4):744-53. {{doi|10.1016/j.ajhg.2012.08.021}}. Epub 2012 Sep 27.</ref><ref>Deloukas P et al. Large-scale association analysis identifies new risk loci for coronary artery disease. DIAGRAM Consortium; CARDIOGENICS Consortium, Nat Genet. 2013 Jan;45(1):25-33. {{doi|10.1038/ng.2480}}. Epub 2012 Dec 2.</ref><ref>Doney AS et al. CARDIoGRAMplusC4D Consortium, Nat Genet. 2013 Jan;45(1):25-33. {{doi|10.1038/ng.2480}}. Epub 2012 Dec 2.</ref><ref>Deloukas P et al. Large-scale association analysis identifies new risk loci for coronary artery disease. CARDIoGRAMplusC4D Consortium, Nat Genet. 2013 Jan;45(1):25-33. {{doi|10.1038/ng.2480}}. Epub 2012 Dec 2.</ref><ref>Berndt SI et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet. 2013 May;45(5):501-12. {{doi|10.1038/ng.2606}}. Epub 2013 Apr 7.</ref><ref>Sabater-Lleal M et al. VTE Consortium; STROKE Consortium; Wellcome Trust Case Control Consortium 2 (WTCCC2); C4D Consortium; CARDIoGRAM Consortium, Wallaschofski H, Smith NL, Tregouet D, Ridker PM, Tang W, Strachan DP, Hamsten A, O'Donnell CJ. Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease. Circulation. 2013 Sep 17;128(12):1310-24. {{doi|10.1161/CIRCULATIONAHA.113.002251}}. Epub 2013 Aug 22.</ref><ref>Holmes MV et al. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol. 2013 Nov 19;62(21):1966-76. {{doi|10.1016/j.jacc.2013.06.044}}. Epub 2013 Jul 31.</ref><ref>Shungin Dɳ̩. et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015 Feb 12;518(7538):187-96. {{doi|10.1038/nature14132}}.</ref><ref>Locke AE the al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015 Feb 12;518(7538):197-206. {{doi|10.1038/nature14177}}.</ref>


He is a member of the executive committee of lots of clinical studies for innovative cardiometabolic active substances.<ref>Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, Kastelein JJ, Keyserling C, Klepp H, Koenig W, L'Allier PL, Lespérance J, Lüscher TF, Paolini JF, Tawakol A, Waters DD Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.Can HDL Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators. Eur Heart J. 2014 Dec 7;35(46):3277-86. {{doi|10.1093/eurheartj/ehu171}}. Epub 2014 Apr 29.</ref><ref>Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE; VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014 Jan 15;311(3):252-62. {{doi|10.1001/jama.2013.282836}}.</ref><ref>Robert J. Glynn, Sc.D., Eleanor Danielson, M.I.A., Francisco A.H. Fonseca, M.D., Jacques Genest, M.D., Antonio M. Gotto, Jr., M.D., John J.P. Kastelein, M.D., Wolfgang Koenig, M.D., Peter Libby, M.D., Alberto J. Lorenzatti, M.D., Jean G. MacFadyen, B.A., Børge G. Nordestgaard, M.D., James Shepherd, M.D., James T. Willerson, M.D., and Paul M Ridker, M.D. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. N Engl J Med 2009; 360:1851-1861April 30, 2009 {{DOI|10.1056/NEJMoa0900241}}</ref><ref>Ladeiras-Lopes R, Agewall S, Tawakol A, Staels B, Stein E, Mentz RJ, Leite-Moreira A, Zannad F, Koenig W. Atherosclerosis: Recent trials, new targets and future directions. Int J Cardiol. 2015 Aug 1;192:72-81. doi: 10.1016/j.ijcard.2015.05.013. Epub 2015 May 8. Review. PMID 26002254</ref>
He is a member of the executive committee of several clinical studies for innovative cardiometabolic active substances.<ref>Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, Kastelein JJ, Keyserling C, Klepp H, Koenig W, L'Allier PL, Lespérance J, Lüscher TF, Paolini JF, Tawakol A, Waters DD Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.Can HDL Infusions Significantly QUicken Atherosclerosis Regression (CHI-SQUARE) Investigators. Eur Heart J. 2014 Dec 7;35(46):3277-86. {{doi|10.1093/eurheartj/ehu171}}. Epub 2014 Apr 29.</ref><ref>Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE; VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014 Jan 15;311(3):252-62. {{doi|10.1001/jama.2013.282836}}.</ref><ref>Robert J. Glynn, Sc.D., Eleanor Danielson, M.I.A., Francisco A.H. Fonseca, M.D., Jacques Genest, M.D., Antonio M. Gotto, Jr., M.D., John J.P. Kastelein, M.D., Wolfgang Koenig, M.D., Peter Libby, M.D., Alberto J. Lorenzatti, M.D., Jean G. MacFadyen, B.A., Børge G. Nordestgaard, M.D., James Shepherd, M.D., James T. Willerson, M.D., and Paul M Ridker, M.D. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. N Engl J Med 2009; 360:1851-1861April 30, 2009 {{doi|10.1056/NEJMoa0900241}}</ref><ref>Ladeiras-Lopes R, Agewall S, Tawakol A, Staels B, Stein E, Mentz RJ, Leite-Moreira A, Zannad F, Koenig W. Atherosclerosis: Recent trials, new targets and future directions. Int J Cardiol. 2015 Aug 1;192:72-81. doi: 10.1016/j.ijcard.2015.05.013. Epub 2015 May 8. Review. {{PMID|26002254}}</ref>


==Honors==
==Joint research projects==
Koenig mobilised external fundings for scientific projects:
⚫
* Fellow of the European Society of Cardiology, FESC (1997, elected)
* European Union Contract QLK4-CT-2002-02236. AIRGENE: Air pollution and inflammatory response in myocardial infarction survivors: Gene-environment-interaction in a high risk group. Core laboratory for biomarkers. (03/2004-03/2007)
⚫
* Fellow of the [[American College of Cardiology]], FACC (1998, elected)
* European Collaborative Project on Inflammation and Vascular Wall Remodelling in Atherosclerosis (AtheroRemo) (HEALTH-2007-2.4.2-1) (06/2008-12/2013)
⚫
* Clinical Hypertension Specialist of the [[European Society of Hypertension]] (2002, elected)
* Cardiovascular net in NGFN. Inflammation and immune response in the pathogenes of type 2 diabetes and atherosclerosis: testing the common soul hypothesis (06/2004-05/2008)
⚫
* Hypertensiologe DHL (2004, elected)
* NGFN-Plus Consortium AtheroGenomics (06/2008- 06/2014). Member of the CHARGE Consortium on GWAS of markers of inflammation and hemostasis.
⚫
* Fellow of the [[Royal College of Physicians]] (Edinburgh), FRCP (2005, elected)
* European Collaborative Project on Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE): HEALTH.2011.2.4.2-2: Evaluation and validation studies of clinically useful biomarkers in prevention and management of cardiovascular diseases. Project no. 278913 (Leader WP 7) (10/2011 – to date). Member of the Steering Committee.
⚫
* Fellow of the [[American Heart Association]],<ref>[http://www.american-heart.de American Heart Association]</ref> FAHA (2006, elected)


==Reviewer==
Together with mit B. Thorand, H. Kolb, S. Martin und C. Herder: DFG Anträge<ref>DFG Anträge Th784/2-1 und TH 784/2-2 von 2001 bis 2011</ref>: Sind inflammatorische Prozesse und eine endotheliale Dysfunktion eine gemeinsame Ursache von [[Diabetes mellitus type 2|Typ 2 Diabetes]] und [[heart attack|Herzinfarkt]]?
⚫
Koenig is a reviewer for medical journals. He is also active for national and international research organisations. He is a member of the Editorial Board of "Clinical Chemistry" and "Atherosclerosis" and was Associate Editor of "Atherosclerosis from 2007 to 2014.

==Memberships in international organisations==
* Member of the New York Academy of Sciences (1981, gewählt)
* Member of the American College of Epidemiology (1988, gewählt)
* Member of the German Cardiac Society/ Dt. Ges. für Kardiologie/ Herz-und Kreislaufforschung
* Member of the American Heart Association
* Member of the American Society of Hypertension
* Member of the Royal Society of Medicine (Edinburgh) (1993, gewählt)
⚫
* Fellow of the European Society of Cardiology, FESC (1997, gewählt)
⚫
* Fellow of the American College of Cardiology, FACC (1998, gewählt)
* Sprecher der Arbeitsgruppe Klinische Epidemiologie der Deutschen Gesellschaft für Kardiologie (1999-2002)
⚫
* Clinical Hypertension Specialist of the European Society of Hypertension (2002, gewählt)
⚫
* Hypertensiologe DHL (2004, gewählt)
⚫
* Fellow of the Royal College of Physicians (Edinburgh), FRCP (2005, gewählt)
⚫
* Fellow of the American Heart Association, FAHA (2006, gewählt)

==Editor==
⚫
Koenig is a surveyor for medical journals. He is also active for national and international research organizations. He is a member of the Editorial Board of "Clinical Chemistry" and "Atherosclerosis" and was Associate Editor of "Atherosclerosis from 2007 to 2014.


== Awards and honors ==
== Awards and honors ==
* 2014 Verleihung der Rudolf Schönheimer Medaille<ref name="Schönheimer">[http://www.dgaf.de/preise/schoenheimer-medaille/ Rudolf Schönheimer Medaille]</ref> der Deutschen Gesellschaft für Atheroskleroseforschung<ref name="DGAF">[http://www.dgaf.de/de/ Deutsche Gesellschaft für Atheroskleroseforschung]</ref>
* 2014 Rudolf Schönheimer Medal<ref name="Schönheimer">[http://www.dgaf.de/preise/schoenheimer-medaille/ Rudolf Schönheimer Medaille]</ref> of the Deutsche Gesellschaft für Atheroskleroseforschung<ref name="DGAF">[http://www.dgaf.de/de/ Deutsche Gesellschaft für Atheroskleroseforschung]</ref>
* 2015 Honorary Award, Lecture on Epidemiology der [[Deutsche Gesellschaft für Kardiologie|Deutschen Gesellschaft für Kardiologie]]
* 2015 Honorary Award, Lecture on Epidemiology of the [[Deutsche Gesellschaft für Kardiologie|German Cardiac Society]]


==Publications==
==Publications==
Koenig is author and co-autthor of more than 600 publications and more than 500 presentations in the field of clinical cardiology (cardiovascular pharmacology, clinical epdimelogy, heart and circulatory epidemology, [[hypertension]] and genetics of cardiovasular disorders).
Koenig ist Autor und Co-Autor von mehr als 600 Veröffentlichungen und mehr als 500 Vorträgen/Postern auf den Gebieten klinische Kardiologie, [[Blutkreislauf|kardiovaskuläre]] Pharmakologie, klinische [[Epidemiologie]], Herz-Kreislaufepidemiologie, [[Hypertension]] und Genetik kardiovaskulärer Erkrankungen


[https://www.researchgate.net/profile/Wolfgang_Koenig4 Publikationsliste ResearchGate]
[https://www.researchgate.net/profile/Wolfgang_Koenig4 Publication list ResearchGate]


[http://www.ncbi.nlm.nih.gov/pubmed/?term=Wolfgang+Koenig Publikationsliste PubMed] (nicht vollständig)
[http://www.ncbi.nlm.nih.gov/pubmed/?term=Wolfgang+Koenig Publication list PubMed] (Selection)


== External links ==
== External links ==
* [http://www.uniklinik-ulm.de/struktur/kliniken/innere-medizin/klinik-fuer-innere-medizin-ii/ag-praeventive-kardiologie/home/wir-ueber-uns/leitung-der-arbeitsgruppe.html Wolfgang Koenig - Leitung der Arbeitsgruppe Präventive Kardiologie Universitätsklinik Ulm]
* [http://www.uniklinik-ulm.de/struktur/kliniken/innere-medizin/klinik-fuer-innere-medizin-ii/ag-praeventive-kardiologie/home/wir-ueber-uns/leitung-der-arbeitsgruppe.html Wolfgang Koenig - Head of the workgroup preventive Cardiology at the University Hospital Ulm, Germany]
* [http://www.bio-pro.de/magazin/thema/00147/index.html?lang=de&artikelid=/artikel/01935/index.html Wehe, wenn die Diabetes-Lawine ins Rollen kommt], Das Biotechnologie und Life Sciences Portal Baden-Württemberg (21.7.2007)


* [http://consumer.healthday.com/general-health-information-16/misc-alcohol-news-13/take-a-pint-and-call-me-in-the-morning-400439.html Take a pint and call me in the morning. Moderate beer quaffers have less heart disease risk, study shows] (Interview with W. Koenig)
* [http://www.bio-pro.de/magazin/thema/07390/index.html?lang=de&artikelid=/artikel/08334/index.html Ulmer Forscher entdecken neuen Biomarker bei Herz-Patienten], Das Biotechnologie und Life Sciences Portal Baden-Württemberg (3.8.2012)


* [https://vimeo.com/33065035 Cario Vascular Clinical Trialists] (CVCT Interview with W. Koenig. Vimeo)
* [http://www.hcc-magazin.com/koerperliche-aktivitat-und-herzerkrankungen-jeder-schritt-zahlt/5265 Körperliche Aktivität und Herzerkrankungen: Jeder Schritt zählt], hcc-Magazin (19.2.2013)


== See also ==
* [http://www.herz-kreislauf-netz.de/index.php?id=23 Entzündung und Immunantwort bei der Pathogenese von Typ 2 Diabetes und Atherosklerose: Testung der Common Soil Hypothesis], Bundesministerium für Bildung und Forschung Nationales Genomforschungsnetz (NGFN)


[[C-reactive protein]]
* [http://www.internisten-im-netz.de/de_news_6_0_1037_mit-biomarkern-das-individuelle-risiko-f-r-herzinfarkt-genauer-bestimmen.html Mit Biomarkern das individuelle Risiko für Herzinfarkt genauer bestimmen], internisten-im-netz.de (13.1.2011)

[[Non-communicable disease]]

[[Cardiovascular disease]]

[[Long-term effects of alcohol consumption]]


== References ==
== References ==
<references />
<references />

{{:DEFAULTSORT:Koenig, Wolfgang}}
[[:Category:Cardiologists]]
[[:Category:German cardiologists]]
[[:Category:German people]]
[[:Category:1949 births]]
[[:Category:Living people]]

Latest revision as of 20:06, 27 October 2022

Wolfgang Koenig

Wolfgang Koenig (born 18 Dezember 1949 in Neuenbürg) is a German cardiologist and university professor. He was assistant medical director at the Department of Internal Medicine II Cardiology, Angiology, Sports medicine and Rehabilitation medicine at the Medical Clinic of the University of Ulm. He is known for his works in the field of evaluation of new biomarkers for cardiological disorders including population genomics and in connection with inflammation, hemostasis and atherosclerosis.

Biography

[edit]

Koenig studied medicine at the Ludwig Maximilians University of Munich from 1969 to 1975. In 1976 he passed the ECFMG in Munich. In 1980 he received his doctorate at the University of Heidelberg. He spent stays abroad till 1983 and was then head of the MONICA Heart Attack Register of the WHO at the Augsburg Hospital from 1983 to 1986. In 1986 Koenig went to the Medical Clinic at the University of Ulm, where he became an internal medicine in 1989. From 1992 on he was a specialist for cardiology. In this year he was habilitated in Ulm. In 1989 he became associate professor and received the additional title Internal Intensive Care in 2005. From 1995 to 2000 Koenig was executive senior physician at the medical hospital and head of the emergency department. From 2003 to 04 he was head of the intensive care unit and from 2004 to 2005 head of the laboratory of heart catheter. Koenig was senior physician at the Department for Internal Medicine II - Cardiology at the Medical University Hospital of the University of Ulm till March 2015. There he headed the laboratory of biomarkers and the clinical center of studies. Beginning of Apil 2015 he joined the German Heart Center Munich at the Technical University of Munich mainly being scientifically active there.

Scientific contribution

[edit]

Koenig provided long experience in research work in the range of epidemology of cardiovascular disorders (built up the MONICA Augsburg heart attack register of the WHO). He delivered fundamental contributions to the inflammation hypothesis of atherosclerosis[1][2][3][4][5][6][7][8][9][10] [11][12][13] and to the importance of hemostaseological factors for atherogenesis[14][15] as well as to genetics of intermediary phenotypes of atherosclerosis.[16][17][18][19][20][21][22][23][24][25][26][27]

He is a member of the executive committee of several clinical studies for innovative cardiometabolic active substances.[28][29][30][31]

Honors

[edit]

Reviewer

[edit]

Koenig is a reviewer for medical journals. He is also active for national and international research organisations. He is a member of the Editorial Board of "Clinical Chemistry" and "Atherosclerosis" and was Associate Editor of "Atherosclerosis from 2007 to 2014.

Awards and honors

[edit]
  • 2014 Rudolf Schönheimer Medal[33] of the Deutsche Gesellschaft für Atheroskleroseforschung[34]
  • 2015 Honorary Award, Lecture on Epidemiology of the German Cardiac Society

Publications

[edit]

Koenig is author and co-autthor of more than 600 publications and more than 500 presentations in the field of clinical cardiology (cardiovascular pharmacology, clinical epdimelogy, heart and circulatory epidemology, hypertension and genetics of cardiovasular disorders).

Publication list ResearchGate

Publication list PubMed (Selection)

[edit]

See also

[edit]

C-reactive protein

Non-communicable disease

Cardiovascular disease

Long-term effects of alcohol consumption

References

[edit]
  1. ^ Koenig W, Sund M, Lowe GD, Lee AJ, Resch KL, Tunstall-Pedoe H, Keil U, Ernst E: Geographical variations in plasma viscosity and relation to coronary event rates. Lancet. 1994 Sep 10;344(8924):711-4
  2. ^ Peters A, Döring A, Wichmann HE, Koenig W. Increased plasma viscosity during an air pollution episode: a link to mortality? Lancet. 1997 May 31;349(9065):1582-7.
  3. ^ Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.Nature. 1998 Jun 25;393(6687):790-3.
  4. ^ Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999 Jan 19;99(2):237-42.
  5. ^ Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet. 2001 Mar 10;357(9258):763-7.
  6. ^ Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004 Mar 23;109(11):1349-53. Epub 2004 Mar 15.
  7. ^ Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005 Aug 2;112(5):651-7. Epub 2005 Jul 25.
  8. ^ Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006 Oct 3;48(7):1369-77.
  9. ^ Spahr A., Klein E., Khuseyinova N., Boeckh C., Pezeshki G., Muche R., Kunze M., Rothenbacher D., Hoffmeister A., Koenig W. Periodontal infections and coronary heart disease: Role of periodontal bacteria and importance of total pathogen burden. The Coronary Event and Periodontal Disease (CORODONT) Study. Arch Intern Med. 2006 Mar 13;166(5):554-9.
  10. ^ Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. JUPITER Study Group. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
  11. ^ Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J. 2009 Nov;30(22):2742-8. doi:10.1093/eurheartj/ehp302. Epub 2009 Aug 7.
  12. ^ Sarwar N et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Emerging Risk Factors Collaboration, Lancet. 2010 Jun 26;375(9733):2215-22. doi:10.1016/S0140-6736(10)60484-9.
  13. ^ Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lp-PLA(2) Studies Collaboration, Lancet. 2010 May 1;375(9725):1536-44. doi:10.1016/S0140-6736(10)60319-4.
  14. ^ Danesh J et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. Fibrinogen Studies Collaboration, JAMA. 2005 Oct 12;294(14):1799-809.
  15. ^ Smith NL et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010 Mar 30;121(12):1382-92. doi:10.1161/CIRCULATIONAHA.109.869156. Epub 2010 Mar 15.
  16. ^ Dehghan A et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011 Feb 22;123(7):731-8. doi:10.1161/CIRCULATIONAHA.110.948570. Epub 2011 Feb 7.
  17. ^ Smith NL et al. Genetic predictors of fibrin D-dimer levels in healthy adults. Circulation. 2011 May 3;123(17):1864-72. doi:10.1161/CIRCULATIONAHA.110.009480. Epub 2011 Apr 18.
  18. ^ Sarwar N et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Lancet. 2012 Mar 31;379(9822):1205-13. doi:10.1016/S0140-6736(11)61931-4. Epub 2012 Mar 14.
  19. ^ Franceschini N et al. Discovery and fine mapping of serum protein loci through transethnic meta-analysis. Am J Hum Genet. 2012 Oct 5;91(4):744-53. doi:10.1016/j.ajhg.2012.08.021. Epub 2012 Sep 27.
  20. ^ Deloukas P et al. Large-scale association analysis identifies new risk loci for coronary artery disease. DIAGRAM Consortium; CARDIOGENICS Consortium, Nat Genet. 2013 Jan;45(1):25-33. doi:10.1038/ng.2480. Epub 2012 Dec 2.
  21. ^ Doney AS et al. CARDIoGRAMplusC4D Consortium, Nat Genet. 2013 Jan;45(1):25-33. doi:10.1038/ng.2480. Epub 2012 Dec 2.
  22. ^ Deloukas P et al. Large-scale association analysis identifies new risk loci for coronary artery disease. CARDIoGRAMplusC4D Consortium, Nat Genet. 2013 Jan;45(1):25-33. doi:10.1038/ng.2480. Epub 2012 Dec 2.
  23. ^ Berndt SI et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet. 2013 May;45(5):501-12. doi:10.1038/ng.2606. Epub 2013 Apr 7.
  24. ^ Sabater-Lleal M et al. VTE Consortium; STROKE Consortium; Wellcome Trust Case Control Consortium 2 (WTCCC2); C4D Consortium; CARDIoGRAM Consortium, Wallaschofski H, Smith NL, Tregouet D, Ridker PM, Tang W, Strachan DP, Hamsten A, O'Donnell CJ. Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease. Circulation. 2013 Sep 17;128(12):1310-24. doi:10.1161/CIRCULATIONAHA.113.002251. Epub 2013 Aug 22.
  25. ^ Holmes MV et al. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol. 2013 Nov 19;62(21):1966-76. doi:10.1016/j.jacc.2013.06.044. Epub 2013 Jul 31.
  26. ^ Shungin Dɳ̩. et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015 Feb 12;518(7538):187-96. doi:10.1038/nature14132.
  27. ^ Locke AE the al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015 Feb 12;518(7538):197-206. doi:10.1038/nature14177.
  28. ^ Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, Kastelein JJ, Keyserling C, Klepp H, Koenig W, L'Allier PL, Lespérance J, Lüscher TF, Paolini JF, Tawakol A, Waters DD Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.Can HDL Infusions Significantly QUicken Atherosclerosis Regression (CHI-SQUARE) Investigators. Eur Heart J. 2014 Dec 7;35(46):3277-86. doi:10.1093/eurheartj/ehu171. Epub 2014 Apr 29.
  29. ^ Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE; VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014 Jan 15;311(3):252-62. doi:10.1001/jama.2013.282836.
  30. ^ Robert J. Glynn, Sc.D., Eleanor Danielson, M.I.A., Francisco A.H. Fonseca, M.D., Jacques Genest, M.D., Antonio M. Gotto, Jr., M.D., John J.P. Kastelein, M.D., Wolfgang Koenig, M.D., Peter Libby, M.D., Alberto J. Lorenzatti, M.D., Jean G. MacFadyen, B.A., Børge G. Nordestgaard, M.D., James Shepherd, M.D., James T. Willerson, M.D., and Paul M Ridker, M.D. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. N Engl J Med 2009; 360:1851-1861April 30, 2009 doi:10.1056/NEJMoa0900241
  31. ^ Ladeiras-Lopes R, Agewall S, Tawakol A, Staels B, Stein E, Mentz RJ, Leite-Moreira A, Zannad F, Koenig W. Atherosclerosis: Recent trials, new targets and future directions. Int J Cardiol. 2015 Aug 1;192:72-81. doi: 10.1016/j.ijcard.2015.05.013. Epub 2015 May 8. Review. PMID 26002254
  32. ^ American Heart Association
  33. ^ Rudolf Schönheimer Medaille
  34. ^ Deutsche Gesellschaft für Atheroskleroseforschung

DEFAULTSORT:Koenig, Wolfgang Category:Cardiologists Category:German cardiologists Category:German people Category:1949 births Category:Living people

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=User:Ventus55/Wolfgang_Koenig&oldid=1118582328"